TITLE:

NMMDA issued a new press communique with respect to Noxafil (posaconazol)

BRIEF:

The National Medicines and Medical Devices Agency (NMMDA) presented a new press communique made by the European Medicines Agency (EMA) on the warning about the difference in dose between the tablet formulation and oral suspension of the respective drug, the two formulations not being able to substitute for one another.